Literature DB >> 2449925

Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase.

O Dreazen1, M Berman, R P Gale.   

Abstract

Median duration of the chronic phase of chronic myelogenous leukemia (CML) is 3 years; less than 20% of patients have a chronic phase greater than 7 years. It is unknown whether the length of chronic phase is stochastic or is predetermined for each patient. Since molecular abnormalities of bcr and c-abl occur in CML, we sought to determine whether there were differences in bcr and c-abl translocation or transcription in individuals with long v short chronic phase. These studies were performed in six patients with CML in whom chronic phase was 7+ to 26 years and 20 patients in whom chronic phase was less than 7 years. All patients had translocation of c-abl to within bcr. The distribution of breakpoints in bcr were similar in both groups. Transcription of the chimeric bcr/c-abl mRNA was comparable. These data suggest that changes in bcr or c-abl alone do not determine the duration of chronic phase in CML; other factors are likely involved.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449925

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Detection of the BCR/ABL fusion gene in chronic myeloid leukemia by RNA polymerase chain reaction.

Authors:  X H Qian; A D Yang; H B Fei; C C Wang
Journal:  J Tongji Med Univ       Date:  1993

2.  Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Authors: 
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

3.  Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.

Authors:  A Grossman; R T Silver; Z Arlin; M Coleman; E Camposano; P Gascon; P A Benn
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.